Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

Benzinga · 1d ago
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.